Curacle Selected as a Presenting Company at Bio USA 2022

[Asia Economy Reporter Lee Chun-hee] Curacle, a company specializing in new drug development for vascular diseases, announced on the 25th that it has been selected as a Presenting Company at the 'Bio International Convention 2022 (Bio USA 2022)' to be held in the United States next month.

Bio USA 2022, held from June 13 to 16 (local time) in San Diego, USA, is a large-scale biotechnology investment conference. As of 2019, before the COVID-19 pandemic, it was the largest bio partnering event in North America, with participation from over 8,400 companies from 65 countries and more than 48,000 meetings held. This year, it will be held offline for the first time since the pandemic.

A total of 210 companies were selected as presenting companies this year. In Korea, along with Curacle, a total of 20 companies were selected, including six listed companies such as Pamemxin, Utilex, Nivec, Oligapass, Biotoxtech, and 14 unlisted companies. Notably, Curacle was consecutively selected as a presenting company at Bio USA following its selection at 'Bio Europe Spring' in March. A Curacle representative stated, “The clinical phase 1 results for our global pipeline are expected to be successful, and with the clinical phase 2 entry of the 'CU101~CU106' projects, which have been actively developed since this year, becoming more visible, it seems we have been consecutively selected as a presenting company.”

At this year's Bio USA, Curacle plans to introduce new projects including 'CU101 (Acute Myocardial Infarction)', 'CU102 (Acute Lung Injury)', 'CU103 (Stroke)', 'CU104 (Ulcerative Colitis)', 'CU105 (Hereditary Angioedema)', and 'CU106 (Combination Therapy for Cancer)', and will actively explore possibilities for joint development and technology transfer (license-out).